Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, monocenter, single arm, phase II trial in 33 patients with
unresectable MPM, who experience disease progression or recurrence after at least one
previous line of platinum-based systemic treatment.
Nivolumab will be administered at a fixed dose of 240 mg every 2 week. Nivolumab will be
given in combination with ipilimumab on week 1, 7, 13 and 19 and will be administered prior
to the infusion of ipilimumab. Ipilimumab will be administered at the dose of 1 mg/Kg.The
patients will receive nivolumab monotherapy on week 3, 5, 9, 11, 15 and 17. From week 21
thereafter, Nivolumab will be then administered every 2 weeks for a maximum period of 2 years
or until disease progression or unacceptable toxicity occurs.